Skip to main content
Terug
SDZNY logo

Sandoz Group AG

Datakwaliteit: 100%
SDZNY
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 76,57
▼ € 0,01 (-0,01%)
Marktkapitalisatie: 33,13B
Dagbereik
€ 75,36 € 77,14
52-Weeksbereik
€ 35,61 € 94,15
Volume
1.235
50D / 200D Gem.
€ 81,21 / € 66,97
Vorige Slotkoers
€ 76,58

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 45,5 0,4
P/B 3,5 2,9
ROE % 8,3 3,8
Net Margin % 8,2 3,9
Rev Growth 5Y % 0,1 10,0
D/E 0,6 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 3,74
€ 3,68 – € 3,80
9,4 B 1
FY2026 € 3,36
€ 3,30 – € 3,41
9 B 1

Belangrijkste Punten

Revenue grew 0,12% annually over 5 years — modest growth
Earnings grew 72765,14% over the past year
Generating 810,00M in free cash flow
P/E of 45,47 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 15,01%
Cash machine — converts 111,16% of earnings into free cash flow

Groei

Revenue Growth (5Y)
0,12%
Revenue (1Y)-14,89%
Earnings (1Y)72765,14%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
8,31%
ROIC6,77%
Net Margin8,24%
Op. Margin15,38%

Veiligheid

Debt / Equity
0,61
Current Ratio1,18
Interest Coverage7,75

Waardering

P/E Ratio
45,47
P/B Ratio3,53
EV/EBITDA27,28
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -14,89% Revenue Growth (3Y) -5,89%
Earnings Growth (1Y) 72765,14% Earnings Growth (3Y) 207,62%
Revenue Growth (5Y) 0,12% Earnings Growth (5Y) -3,21%
Profitability
Revenue (TTM) 8,84B Net Income (TTM) 728,65M
ROE 8,31% ROA 3,31%
Gross Margin 47,02% Operating Margin 15,38%
Net Margin 8,24% Free Cash Flow (TTM) 810,00M
ROIC 6,77% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,61 Current Ratio 1,18
Interest Coverage 7,75 Dividend Yield 0,01%
Valuation
P/E Ratio 45,47 P/B Ratio 3,53
P/S Ratio 3,75 PEG Ratio 0,00
EV/EBITDA 27,28 Dividend Yield 0,01%
Market Cap 33,13B Enterprise Value 37,08B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 8,84B 10,38B 9,98B 8,60B 8,79B
Net Income 728,65M 1,00M 77,00M 784,05M 830,15M
EPS (Diluted) 1,67 0,00 0,18 1,82 1,93
Gross Profit 4,16B 4,93B 4,56B 4,05B 4,15B
Operating Income 1,36B 307,00M 375,00M 1,15B 1,38B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22,03B 19,91B 19,43B 16,23B 15,98B
Total Liabilities 12,65B 11,74B 10,78B 22.861,0 8,55B
Shareholders' Equity 9,38B 8,16B 8,65B 77.139,0 7,43B
Total Debt 5,68B 4,85B 4,55B 3,87B 4,51B
Cash & Equivalents 1,74B 1,19B 1,11B 74,00M 36,45M
Current Assets 8,17B 7,80B 7,57B 100.000,0 5,07B
Current Liabilities 6,90B 6,31B 5,70B 22.861,0 7,62B